![Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ](https://www.bmj.com/content/bmj/378/bmj-2022-070346/F2.large.jpg)
Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ
![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and.png)
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
![Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The](https://www.thelancet.com/cms/attachment/2cbba9be-95f0-4764-ad55-25b5e2074383/gr1.gif)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
![Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/c787f601-c0f2-4f8b-b5f9-710b7ccfcbff/cncr29082-fig-0002-m.jpg)
Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library
![The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40271-021-00552-w/MediaObjects/40271_2021_552_Fig1_HTML.png)
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink
![IKCS 2022: Real-world Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma Receiving Pembrolizumab + Axitinib vs Ipilimumab + Nivolumab IKCS 2022: Real-world Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma Receiving Pembrolizumab + Axitinib vs Ipilimumab + Nivolumab](https://www.urotoday.com/images/com-doc-importer/91-ikcs-2022/ikcs-2022-real-world-clinical-outcomes-of-patients-with-metastatic-renal-cell-carcinoma-receiving-pembrolizumab-axitinib-vs-ipilimumab-nivolumab/image-0.jpg)
IKCS 2022: Real-world Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma Receiving Pembrolizumab + Axitinib vs Ipilimumab + Nivolumab
![Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f10fa33d-cf21-48d9-862f-0a70a29890a5/gr1_lrg.jpg)
Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology
![JCM | Free Full-Text | Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy JCM | Free Full-Text | Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy](https://www.mdpi.com/jcm/jcm-11-01500/article_deploy/html/images/jcm-11-01500-g001.png)
JCM | Free Full-Text | Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://www.thelancet.com/cms/attachment/8b10cd73-be2f-4363-ba25-eb395b6c06c4/gr2_lrg.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials Marc E. Buyse. - ppt download Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials Marc E. Buyse. - ppt download](https://images.slideplayer.com/32/10101651/slides/slide_13.jpg)
Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials Marc E. Buyse. - ppt download
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)